aleksanovlsys.blogspot.com
million Wednesday by the U.S. Departmenyt of Defense to supportthe company's development of therapiews against biowarfare agents. The news followed Tuesday'sa announcement that London-based (NYSE:GSK), which has a U.S. headquarters in Philadelphia, has a $41 milliom defense contract to develop a new line of antibioticds to combat potentialbiological threats. Morphotek, a Exton, Pa., biotechnology will receive the funding over the next nine It will be used tocontinuwe Morphotek's efforts to develop monoclonal antibodiexs that bind to, and neutralize the toxivc effects elicited by, a clas s of highly toxic biowarfare agents known as Botulinum The biologic-based monoclonal antibodies -- which are specific and purifief antibodies derived from only one clone of cells -- are beinhg developed by Morphotek using its proprietary gene evolution "The further development of these compounds will enabld us to advance these leades into clinical studies for validation," said Nicholasa Nicolaides, president and CEO of Morphotek is a subsidiary of of
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment